Search

Your search keyword '"Qunaj, Lindor"' showing total 12 results
Start Over Author "Qunaj, Lindor"
12 results on '"Qunaj, Lindor"'

6. Prognostic Factors for North American Adult T Cell Leukemia Lymphoma: Defining Risk Groups Using a Four-Point Score Prognostic System

Author

Rahman, Shafia, primary, Soto, Alvaro Alvarez, additional, Qunaj, Lindor, additional, Ye, Kenny, additional, Pradhan, Kith, additional, Thakkar, Astha, additional, Cui, Zhu, additional, Meron, Michal Kasher, additional, D'Aiello, Angelica, additional, Lombardo, Amanda, additional, Mustafa, Jennat, additional, Khatun, Fariha, additional, Gillick, Kailyn, additional, Joseph, Felisha, additional, Naik, Anjali, additional, De Castro, Alyssa, additional, Steidl, Ulrich G., additional, Wang, Hao, additional, Ren, Xiaoxin, additional, Zang, Xingxing, additional, Derman, Olga, additional, Gritsman, Kira, additional, Kornblum, Noah, additional, Shastri, Aditi, additional, Mantzaris, Ioannis, additional, Goldfinger, Mendel, additional, Braunschweig, Ira, additional, Ye, B. Hilda, additional, Verma, Amit, additional, Janakiram, Murali, additional, Shah, Urvi A, additional, and Sica, R. Alejandro, additional

Published
2020
Full Text
View/download PDF

12. Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base.

Author

Qunaj, Lindor, Castillo, Jorge J., and Olszewski, Adam J.

Subjects
*B cell lymphoma, *LYMPHOMAS, *HERPESVIRUS diseases, *TREATMENT of rare diseases, *CASTLEMAN'S disease, *PATIENTS
Abstract

Using records from the National Cancer Data Base, we studied overall survival of CD20-negative variants of diffuse large B-cell lymphoma (DLBCL): primary effusion (PEL, N = 228), plasmablastic (PBL, N = 481), ALK-positive large B-cell (ALK + LBLC, N = 15), and human herpesvirus-8-positive DLBCL (HHV8 + DLBCL, N = 77). Three-year survival was 27% for PEL, 40% for PBL, 34% for ALK + LBCL, and 63% for HHV8 + DLBCL. Compared with unspecified DLBCL, and adjusting for clinical characteristics (including the HIV status), survival was significantly worse for PEL (hazard ratio [HR], 1.58; 95% confidence interval [CI], 1.31-1.90), PBL (HR 1.66; 95% CI, 1.41-1.95), and ALK + LBCL (HR, 2.70; 95% CI, 1.27-5.75), but not for HHV8 + DLBCL (HR, 0.89; 95% CI, 0.54-1.45). The HIV status was not an independent prognostic factor in PEL, PBL, or HHV8 + DLBCL. Advanced stage was prognostic for PBL (p = .0002), but not for ALK + LBCL (p = .96), or HHV8 + DLBCL (p = .28). In PEL and PBL survival significantly differed according to primary site. Novel therapeutic approaches are urgently needed for these rare diseases. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results